Symbol="ASLN"
AssetType="Common Stock"
Name="Aslan Pharmaceuticals Ltd ADR"
Description="ASLAN Pharmaceuticals Limited, a biopharmaceutical company focused on clinical phase immunology, is dedicated to developing various treatments to transform the lives of patients. The company is headquartered in Singapore."
CIK="1722926"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="83 CLEMENCEAU AVENUE, #12-03 UE SQUARE, SINGAPORE, SG"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="36616100"
EBITDA="-54072000"
PERatio="None"
PEGRatio="None"
BookValue="0.667"
DividendPerShare="0"
DividendYield="0"
EPS="-3.76"
RevenuePerShareTTM="0.005"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.447"
ReturnOnEquityTTM="-2.094"
RevenueTTM="189710"
GrossProfitTTM="79821000"
DilutedEPSTTM="-3.76"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="15.67"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="19.05"
PriceToBookRatio="1.584"
EVToRevenue="16.94"
EVToEBITDA="-0.062"
Beta="1.797"
num_52WeekHigh="4.945"
num_52WeekLow="1.702"
num_50DayMovingAverage="3.372"
num_200DayMovingAverage="3.182"
SharesOutstanding="16347200"
DividendDate="None"
ExDividendDate="None"
symbol="ASLN"
open="2.35"
high="2.38"
low="2.18"
price="2.24"
volume="56932.00"
latest_trading_day="2023-08-02"
previous_close="2.37"
change="-0.13"
change_percent="-5.4895%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="42"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="58"
Volume_recent_avg="116060"
Change_recent_avg="0.01"
Delta_recent_avg="0.27"
Variance_recent_avg="0.14"
Change_ratio_recent_avg="-0.27"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="58"
Aroon_momentum_negative="42"
image_negative_thumbnail_id_1="166"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0010.jpeg"
image_negative_thumbnail_id_2="142"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0034.jpeg"
image_neutral_thumbnail_id_1="582"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0017.jpeg"
image_neutral_thumbnail_id_2="527"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0072.jpeg"
image_positive_thumbnail_id_1="995"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0157.jpeg"
image_positive_thumbnail_id_2="665"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0043.jpeg"
image_professor_thumbnail_id_1="1194"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0028.jpeg"
image_professor_thumbnail_id_2="1182"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0016.jpeg"
